Navigation Links
Symposium to look at genetic basis of exercise
Date:3/17/2009

BETHESDA, Md. (Mar. 18, 2009) 'Adaptation to exercise' is a familiar phenomenon, even if the phrase is not: A sedentary person takes up jogging and can barely make it around the block. After jogging regularly for a few weeks, the person can jog a mile, then two, then three. With regular exercise, the body adapts, becoming fitter and more efficient. The heart can pump more blood, delivering more oxygen to the muscles. The muscles get stronger, and so on.

There are individual differences in the ability to adapt to exercise. Some sedentary individuals who take up jogging will be able to run three miles after a short training period, while others will take much longer to get to the same level. What accounts for this difference in a person's ability to adapt to exercise? One important factor is our genes.

Research into the role genes play in exercise has been gaining steam over the past few decades and is the topic of a symposium at the Experimental Biology conference in New Orleans on April 20. Mark Olfert of the University of California at San Diego and Claude Bouchard of the Pennington Biomedical Research Center have organized the symposium, the Genetics of the Adaptation to Exercise. The American Physiological Society is sponsoring the symposium.

Speakers at the symposium will include Eric Hoffman of the Children's National Medical Center, Washington, D.C. and Tuomo Rankinen of the Pennington Biomedical Research Center. Dr. Hoffman will discuss Genetics and skeletal muscle adaptation to exercise, while Dr. Rankinen will talk on Genetics and the response to exercise in human populations. The symposium will also include presentation of selected abstracts.

Focus on individual genes

So far, scientists have identified about 200 genes that play a role in the body's ability to adapt to exercise. Although the research includes the term 'exercise' this work extends well beyond athletic performance. For example, it will
'/>"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Public Policy Center hosts flood symposium March 10-12
2. AAAS Symposium: Emerging threats to tropical, temperate and ocean ecosystems
3. Symposium at UH will address how to put sustainability into practice
4. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
5. Childrens National convenes first childhood obesity symposium
6. CTRC-AACR San Antonio Breast Cancer Symposium
7. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
8. Counter-terrorism symposium held at NJIT tomorrow
9. AVS 55th International Symposium & Exhibition, Oct. 19-24
10. Penn presents inaugural symposium on applied mathematics and computational science
11. Ansary Symposium on Stem Cell Research at Weill Cornell Medical College
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a complex cocktail of poisonous peptides that immobilize animal ... this cocktail damage only insects, which is why a ... a safe and ecologically sound pesticide. Prof. Michael ... has isolated the genetic sequences for important neurotoxins in ...
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... COLUMBUS, Ohio Blocking the function of an enzyme in ... prevent nerve cells from dying after a stroke, new research ... found that the tocotrienol form of vitamin E, an alternative ... fatty acids that eventually kill neurons. The Ohio State ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2A new species of lichen discovered in the Iberian Peninsula 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced the ... venture will bring the world’s most efficient gas dissolution technology to all of ... to both the industrial and municipal markets. With offices located in Sarasota, Sebring ...
(Date:7/27/2015)... July 27, 2015 Junto Health, a company ... information and develop new technology solutions, today announced the ... (SPG), a leader in health care policy consulting. Working ... in a collaborative innovation process while, at the same ... in public policy, health care finance and the delivery ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... ... ... VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency ... opportunities. , “We are very excited to be able to partner with VetStem Biopharma ... therapy is an established treatment for arthritic conditions in our pets and is also ...
Breaking Biology Technology:BlueInGreen Brings Water Treatment Technology to Florida 2Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
... Mouse monoclonal antibody raised ... Immunogen: ... 206 a.a) partial recombinant protein ... Accession Number: NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
Biology Products: